Significantly, clinical research has demonstrated that IDH mutations frequently work in concert with co-mutations such as FLT3-ITD and NRAS, which collectively stimulate the RAS/MAPK and PI3K/AKT signaling pathways, hence facilitating the aberrant survival and proliferation of AML cells (76). This evidence concerns the gene IDH2 and acute myeloid leukemia.